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ABSTRACT
Urinary carcinoma is one of the most prevalent cancers across the United States
and is among the leading cause of cancer related morbidities. With muscle-invasive
urinary carcinoma having only 15% survival at stage T4, diagnostic tools of this type of
cancer is necessary. This work sought to characterize a model of urothelial carcinoma
into a specific muscle-invasive bladder cancer subtype, which has important implications
in for prognosis, development of targeted therapeutic agents, and disease management.
Our laboratory has developed an immortalized uroepithelial cell line, UROtsa, which can
be malignantly transformed by arsenite (As+3) and Cd2+ and has been shown to produce
colonies on soft agar and tumors in nude mice. We therefore sought to determine if which
subtype of muscle-invasive bladder cancer in our six As3+ and seven Cd2+-transformed
cell lines and heterotransplant tumors. Real-time reverse transcriptase polymerase chain
reaction (RT-PCR) was used to determine mRNA levels of 25 marker genes of basal and
luminal subtypes of muscle-invasive bladder cancer. Western blotting and
immunohistocemical analysis of select markers was used to evaluate protein expression.
Data indicated that the expression of the 25 marker genes in the As3+ and Cd2+transformed tumors was increased in the basal subtype compared to the luminal subtype.
This same expression pattern was also seen in the transformed As3+ and Cd2+ cell lines
and spheroids, or putative cancer stem cells, derived from our transformed cell lines via
culture in serum-free media in low attachment flasks. Next, we sought to determine the
mRNA and protein expression in our non-tumorigenic parental UROtsa cell line. We
determined the parental UROtsa cell line had increased expression of the basal marker
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genes and this was further increased in the spheroids, while expression of the luminal
marker genes was seen to be further decreased in expression in the spheroids.
Due to the observations seen in the mRNA expression of the spheroids, we
became interested in the ability of these cells to maintain their gene signature when
replaced back into the cell culture conditions of the original cell line. To do this, one As3+
cell line was grown in serum media and cell culture flasks that promote attachment. From
there, the cells were placed into low attachments flasks with serum-free media to produce
spheroids. Once grown, the cells were reintroduced into cell culture flasks that promote
cell attachment with serum-containing media and harvested once reaching confluency
(P1) and passages 4 and 8 (P4 and P8). Microarray analysis of these samples found that
there were 4,415 differentially expressed genes when comparing the original cell line to
the spheroid. This number decreased at each comparison of the passages to the cell line
with 1,290, 452, and 191 differentially expressed genes compared to the cell line at P1,
P4, and P8 respectively. This data indicated that the replacement of our spheroids into
cell culture conditions identical to the original cell line promoted the reversal of the
spheroids into our original cell line cultures. We next sought to understand if the gene
signature of the spheroids would be maintained if they were cultured in conditions of
flasks that promote cell attachment with serum-free media in the same As3+ transformed
cell line, but also a Cd2+ cell line and our original parental UROtsa cell line. By
performing real-time RT-PCR analysis of the 25 muscle-invasive bladder cancer marker
genes, we found the number of differentially expressed genes compared to the cell line
and either the spheroid or subsequent passages was relatively stable with at least 68% of
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the genes being differentially expressed by P8. This data demonstrates we have a unique
gene signature that does not align with the original cell line.

xv

CHAPTER I
INTRODUCTION
Urinary Carcinoma
Urinary carcinoma accounts for a significant number of cancer morbidity and
mortality with an estimated 430,000 new cases diagnosed in 2012 (Antoni, et al., 2016)
and 115,000 deaths each year (Meliker & Nriagu, 2007). Incidence rates are 3 to 4 times
higher in men than in women and the disease prevalence increases with age; 80% of cases
in occur in patients ages 50 to 79 (Wai & Miller, 2002). Despite this type of cancer being
only the fourth most common in males and ninth most common in females (Crawford,
2008), it is the most expensive cancer from diagnosis to death with the annual cost in 2013
being $US4.25 billion (Yeung, Dinh, & Lee, 2014).
Urinary carcinoma typically arises from the transitional cells of the bladder, termed
the urothelium, and accounts for 95% of all diagnosed cases (Malats & Real, 2015). These
tumors can be of two types: a low-grade, non-invasive tumor, which occurs 70% of the
time with high rates of recurrence, but infrequently progresses to muscle invasion or an
aggressive, muscle-invasive disease with 5-year survival rates of less than 50% (Yousef &
Gabril, 2017).
Anatomy of the Urinary Bladder
The urinary bladder is a muscular organ that functions to collect and store urine
before it is excreted from the body. As mentioned above, the bladder consists of specialized
epithelial cells called the urothelium, which has properties to allow for filling and voiding
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in at least two ways. First, the bladder, much like the stomach, is highly wrinkled, which
allows for the storage of urine by unfolding of the walls of the bladder. Secondly, during
filling, the urothelium becomes thinner due to a change in the morphology of the cells that
it is comprised of (Apodaca, 2004). Three types of cells coat the surface of the urothelium:
umbrella, intermediate, and basal cells. The outermost cells are the umbrella cells that are
unique to the urothelium and which form a barrier that functions to prevent the entry of
pathogens and controls the intake of molecules into the underlying tissues layers. Sitting
just below the umbrella cells are the intermediate cells that may be one to several layers
thick and are rapidly regenerated. The bottom-most layer of the urothelium is comprised
of the basal cells, which form a single layer that is in contact with the connective tissue
below. These cells have a low mitotic index and contain the urothelial stem cells, which
play a critical role in regeneration.
The sub-urothelium or lamina propria is comprised of an extracellular matrix,
which contains fibroblasts, adipocytes, nerve endings, blood vessels, and the muscularis
mucosae muscle layer. Deep to this layer is the detrusor layer that contains three layers of
smooth muscle bundles of the detrusor muscle (inner longitudinal, middle circular, and
outer longitudinal) along with connective tissue and interstitial cells. This muscle of the
bladder is covered by a thin membranous connective tissue termed the external serosa and
is surrounded by perivesical fat in the abdominal cavity.
Signs and Symptoms of Urinary Carcinoma
The most common symptom of urinary carcinoma is gross painless hematuria, also
known as the presence of blood in the urine. This symptom presents itself in 85% of
patients at initial diagnosis (Alishahi, Dyrne, Goodman, M., & Baxby, 2002). The second
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most common symptom is asymptomatic microscopic hematuria with up to 10% of patients
diagnosed with urinary carcinoma (Metts, Metts, Milito, & Thomas Jr., 2000). A study of
1,046 patients, 657 and 389 presenting with microscopic and gross hematuria respectively,
found that 25% of those presenting with gross hematuria had a urological malignancy
compared to only 3.7% of patients with microscopic hematuria (Alishahi, Dyrne,
Goodman, M., & Baxby, 2002). In addition, of the 1,930 patients enrolled in a study at a
hematuria clinic, 12% were found to have urinary carcinoma (Khadra, Pickard, Charlton,
Powell, & Neal, 2000). The remaining patients that do not present with the symptoms
mentioned above do present with signs that mimic other common urological diseases, such
as urinary tract infections.
Muscle-Invasive Urinary Carcinoma
At the time of diagnosis, approximately one-third of urinary tumors present as nonpapillary lesions and have a high propensity for metastasis (Malkowicz, et al., 2007). These
tumors consist of those staged from T2 to T4. These high-grade tumors have overall 5-year
survival rates of 68% for patients with a T2 diagnosis to only 15% for those with T4
(Goebell & Knowles, 2010). The invasion of a tumor into the muscularis propria is staged
as T2, while stages T3 and T4 are characterized by the invasion of the perivesical soft tissue
or invasion into an adjacent organ, which include the vagina, uterus, prostate, pelvic wall
or abdominal wall, respectively (Cheng, Montironi, Davidson, & Lopez-Beltran, 2009).
With evidence supporting differences in morphology and survival rates, it is hypothesized
that there are separate oncogenic pathways for non-invasive and muscle-invasive tumors.
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Animal studies have proposed the expression of the SV40 large T antigen to
inactivate the tumor protein p53 (TP53) and retinoblastoma (RB) pathways to induce nonpapillary, invasive urinary carcinoma (Zhang, Pak, Shapiro, Sun, & Wu, 1999). The p53
family of transcription factors functions to regulate vital cell processes, which include
differentiation, proliferation, and control over cell death and survival (Kaghad, et al.,
1997). The RB1 protein is a negative regulator of the cell cycle by controlling progression
through the G1 phase (Goodrich, Wang, Yue-Wei, Lee, & Lee, 1991). Inactivation of both
TP53 and RB proteins leads to loss of cell cycle control, which in turn affects many aspects
of tumorigenesis, such as differentiation, survival, senescence, and genomic stability.

Figure 1. Urinary carcinoma staging according to the TMN system (Adapted from
van der Meijden A. P., 1998).
19

Another

frequently

found

mutation

in

invasive

bladder

tumors

is

phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] phosphatase and tensin
homolog (PTEN). PTEN is involved in the conversion of lipid second messengers, which
antagonizes signaling cascades downstream of receptor tyrosine kinases (RTKs) and
phosphatidylinositol-3-kinase (PI3K) (Maehama & Dixon, 1998). The inactivation of
PTEN leads to the dysregulation of the mammalian target of rapamycin pathway (mTOR),
which in turn inhibits its blocking of bladder tumors (Puzio-Kuter, et al., 2009).
Diagnosis of Muscle Invasive Urinary Carcinoma
Muscle-invasive tumors are diagnosed after further investigation into the cause of
hematuria. While urine cytology studies have poor sensitivity in detecting low-grade
cancers (Badalament, Fair, Whitemore Jr., & Melamed, 1988), they are highly predictive
of high-grade cancers (Droller M. J., 1998). Recently, there have been proposed markers
in voided urine that may help in the detection of bladder cancer. A promising assay, the
bladder tumor antigen (BTA) test, detects the release of extracellular matrix proteins from
urinary carcinoma (Sarodsy, et al., 1997). However, specificity of high-grade carcinomas
may be affected by infections of the urinary tract, the presence of stones, and other causes
of inflammation, which deems this assay unreliable for cancer detection (Droller M. J.,
1998). A second molecule being tested for its potential as a diagnostic tool for urinary
carcinoma is telomerase, a ribonucleoprotien enzyme that functions to produce telomeres
(Lin, et al., 1996). Detection of telomerase levels in voided urine have been found to have
a sensitivity of 87.5% for high-grade tumors and an overall specificity of 70% for both
low- and high-grade tumors (Kavaler, Landman, Y, Droller, & Liu, 1998).
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Treatment of Muscle Invasive Urinary Carcinoma
Along the same ideals as low-grade tumors, the standard treatment for muscle
invasive urinary carcinoma is radical cystectomy with lymph node dissection (Sridhar,
2017). This procedure is not without drawbacks; in up to as much as 64% of patients,
radical cystectomy leads to peri- and postoperative complications within the first three
months post-surgery (Donat, et al., 2009) and failure occurs in 70% to 80% of patients with
aggressive disease (Skinner & Lieskovsky, 1984).
With the global life expectancy increasing yearly, there will be a larger population
of patients with bladder cancer who have an advanced disease and radical cystectomy will
no longer be a viable option for treatment. A study found that 25% of patients ages 70-79
and 40% of patient’s ages 80-89 were treated with observation alone (Gray, et al., 2013).
In addition, younger patients who wish to avoid the complications associated with radical
cystectomy may be candidates for other types of treatments, which include partial
cystectomy, transurethral resection of the bladder tumor (TURBT), chemotherapy and
radiation therapy.
In order to give patients a better chance of survival and remission, neoadjuvant and
perioperative chemotherapies have been developed. For neoadjuvant chemotherapy,
cisplatin-based is recommended by both the North American and European guidelines
(Clark, et al., 2016) (Witjes, et al., 2016). Different combinations of drugs have been tested
and

common

regimens

include

methotrexate,

vinblastine,

doxorubicin,

and

cyclophosphamide (MVAC) and gemcitabine plus cisplatin (GC) (Galsky, et al., 2015).
For those who are unfit for cisplatin-based therapy and those who fail to respond to such
treatment, other options have been explored, such as carboplatin-based drug combinations
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that have resulted in overall survival rates of 9 months (De Santis, et al., 2012). By instilling
this multidisciplinary approach to treating urinary carcinoma, hopefully more patients will
have an easier time managing their disease, a better quality of life, and have more positive
outcomes.
The need for more therapy options for bladder tumors and the investigation of
immunotherapies for other types of cancers has led to the development of drugs as new
treatment tools. One therapeutic avenue that has emerged as a promising target is the
programmed cell death protein 1 (PD-1) and programmed death ligand 1/2 (PD-L1/2)
pathway. Under homeostatic conditions, PD-1 functions to regulate T cell responses by
interacting with PD-L/1/2. However, in urinary carcinoma, PD-1 and PD-L1 are
upregulated, which through their interaction promotes T-cell exhaustion (Tumeh, et al.,
2014). By blocking the interaction with the PD-1 receptor with antibodies, there is a
restoration of T-cell function (Chism, 2017).
Molecular Subtypes of Muscle-Invasive Urinary Carcinoma
Understanding the molecular expression patterns of heterogeneous tumors could
lead to improved therapeutic strategies by finding new molecules to target and give insight
into how individual tumors will respond to therapies. This was first accomplished by
analyzing gene expression patterns in normal and malignant breast cancer tissue along with
cell lines and clustering all the samples according to their patterns of expression. The study
found four groups of samples that had different molecular features and were named
ER+/luminal-like, basal-like, Erb-B(II) and normal (Perou, et al., 2000). This same idea
has been used to understand the phenotypic diversity of many types of cancer including
urinary carcinoma.
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An investigative group from the University of North Carolina at Chapel Hill sought
to understand the intrinsic molecular subtypes of high-grade bladder carcinoma. By
analyzing 262 high-grade muscle-invasive tumors from public datasets and 49 high-grade
tumors, they found two groups, named K1 and K2, which had different gene expression
signatures. Clustering of the K1 data set found high levels of the high molecular weight
keratins, specifically keratin 14 (KRT14), keratin 5 (KRT5), and keratin 6B (KRT6B),
along with the cluster of differentiation molecule 44 (CD44). Conversely, the K2 cluster
expressed high levels of uroplakins, specifically uroplakin 1B (UPK1B), uroplakin 2
(UPK2), and uroplakin 3 (UPK3), and the low molecular weight keratin, keratin 20
(KRT20). Furthermore, they performed ingenuity pathway analysis (IPA) and found the
tumors in the K1 cluster were associated with carcinogenesis and cell survival and
movement (Damrauer, et al., 2014).
A second group from Lund University in Sweden analyzed 144 urinary carcinomas
by whole genome array-comparative genomic hybridization and mutational analysis of
genes known to be implicated in the development of urinary tumors. Their clustering
results found two intrinsic molecular subtypes, which they proceeded to name MS1 and
MS2. Further analysis of the two groups found distinct enrichment of genes between the
subtypes with cell cycle genes, cellular transformation, and genomic instability in the MS2
subtype. Taken together, these particular gene enrichments suggest the MS2 subtype to be
more aggressive than MS1. The mutational analysis found distinct patterns for mutations
in the genes implicated in the two hypothesized pathways of the development of urinary
carcinoma. Activating mutations in fibroblast growth factor receptor 3 (FGFR3)/
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) were
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found in the MS1 tumors, while alterations in TP53/ MDM2 proto-oncogene (MDM2) and
a loss of RB1 were significant in MS2 tumors (Lindgren, et al., 2010).
A follow-up study by this group extended their previous research and found 5 major
subtypes of urinary carcinoma: urobasal A, urobasal B, genomically unstable, squamouscell carcinoma (SCC) like, and a heterogeneous, infiltrated group. The urobasal A tumors
had elevated expression levels of FGFR3, cyclin D1 (CCND1), and tumor protein 63
(TP63) and showed a good prognosis. The genomically unstable tumors were characterized
by TP53 mutations and genes found to be associated with tumor progression and
recurrence, such as karyopherin subunit alpha 2 (KPNA2) and heme oxygenase 1
(HMOX1) (Staack, et al., 2002). High expression of the basal keratins KRT4, KRT6A,
KRT6B, KRT6C, KRT14, and KRT16 were found in the SCC-like tumors. The urobasal
B tumors were enriched in FGFR3 mutations along with FGFR3, CCND1, and TP63 gene
expression, similar to the urobasal A subtype. However, this group showed expression of
some keratins of the SCC-like group and TP63 mutations, which led researchers to believe
this group is more progressed than the urobasal A group. Finally, the infiltrated tumor
group was characterized by the presence of immunologic and myofibroblast cells (Sjödahl,
et al., 2012).
The final investigative team to pioneer this research in urinary carcinoma out of the
University of Texas MD Anderson Cancer Center performed whole genome mRNA
expression profile on 73 TURBT muscle-invasive samples. By doing this they identified
three distinct subtypes: basal, luminal, and p53-like. The basal tumors were characterized
by upregulated gene expression of CD44, KRT5, KRT6, KRT16, and CDH3 and was
associated with shorter overall survival and disease-specific survival. On the other hand,

24

luminal tumors were enriched in high expression and mutations of FGFR3. The
transcription factors peroxisome proliferator activator receptor gamma (PPARγ) and its
coactivator fatty acid binding protein 4 (FABP4) were also found to be strongly expressed
in luminal tumors (Choi, et al., 2014).
Taken altogether, more aggressive tumors in the above studies, namely basal, were
characterized by areas of squamous differentiation and high expression of high molecular
weight keratins (KRT5, KRT6, KRT14, and KRT16) along with CDH3 and CD44. These
tumors were found to have mutations in RB1 and were associated with shorter overall
disease-specific survival and carcinogenesis. In contrast, tumors that were found to be less
aggressive, or luminal, were characterized by mutations in FGFR3 and high expression
levels of uroplakins and KRT20 along with the transcription factors PPARγ and FABP4.
Tumor-Derived Spheroids as an In Vitro Model System
Two-dimensional (2D) monolayer cell cultures are an indispensable tool that
allows researchers to understand many functions and characteristics of tissue samples, as
well as an excellent model to test new therapeutics without using animals. However,
recent discoveries have found that three-dimensional (3D) cell culture models offer
benefits that 2D cultures cannot. For example, in 2D cultures, cancer cells rely on
adherence to a flat surface and thus all cells are exposed to a similar amount of nutrients
and growth factors, but 3D cultures can more closely mimic the in vivo environment
where cells in the center of a tumor would be hypoxic and have reduced proliferation.
One type of 3D cell culture model system utilizes the growth of cancer cell lines
in low-attachment cell culture flasks and serum-free media, which produces spherical,
free-floating cells, which are named tumorspheres or spheroids. This type of cell
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culturing allows for the growth and expansion of a subpopulation of cells from the overall
cell line, in which the cells show characteristics of cancer stem cells. The first description
of cancer stem cells in free-floating culture came from the dissociation of brain tumors
(Singh, et al., 2003) and in the subsequent years, a wide range of solid tumors and cancer
cell lines have given rise to spheroids. This type of stem cell shares characteristics with
typical stem cells such as self-renewal and pluripotent capacity (Reya, Morrison, Clarke,
& Weissman, 2001). Although they have these features, cancer stem cells are a distinct
population of cells that are essential for the development of a tumor and their relationship
to the overall population of cells in culture is unknown.
Risk Factors of Urinary Carcinoma
The lifestyle choices that we make have a large impact on our health. Some of these
decisions leave us more susceptible to developing specific types of cancer. For urinary
carcinoma, many risk factors increase a person’s chances of developing this type of cancer.
To illustrate this, research has found that men who smoke have a two-fold increase in
developing bladder tumors, while women who smoke have a four-fold increase compared
to those who never smoke (Reedman, Silverman, Hollenbeck, Schatzkin, & Abnet, 2011).
On the contrary, there was found to be no association of alcohol and no strong association
of coffee with urinary carcinoma (Pelucchi & La Vecchia, 2009).
Environmental risk factors also play a role in the development of urinary tumors.
For those who reside in Egypt and other countries in the eastern hemisphere, schistosoma
haematobium (S. haematobium), whose life cycle is in freshwater snails and humans, has
been found to cause 27% of urinary carcinoma cases in Cairo, Egypt (Elsebai, 1977). The
most notable environmental risk factor of urinary carcinoma is occupational exposures.
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Over a century ago, it was first noted that dye workers in Germany were found to have
incidence of bladder tumors (Johansson & Cohen, 1998). It was found that the causative
agent was 2-Naphthylamine, a now recognized carcinogenic agent of bladder cancer
(Humans, 2010). Since then, it has been estimated that urinary carcinoma from
occupational exposures has resulted in up to 27% of the total number of cancers (Delclos
& Lerner, 2008).
Heavy Metals
Of particular interest to our laboratory are the heavy metals arsenic and cadmium
(Cd2+), two of the four heavy metals that are known to be carcinogenic to humans (Ernst
& Theriault, 1984). Since both of these heavy metals have been associated with an
increased risk of many cancers, they have been designated by the International Agency for
Research as a Group 1 human carcinogen (Cancer, Cadmium and Cadmium Compounds,
1993) (Cancer, Arsenic and Arsenic Compounds, 2002).
Exposure and Metabolism of Arsenic
Of the three biological groups of arsenic compounds, inorganic arsenic (iAs) is
associated with acute and chronic effects through two common ways of exposure:
inhalation from industrial sources or ingestion of contaminated drinking water. In addition,
arsenic is present in soil with concentrations up to 40µg/g (Cancer, Monographs on the
Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Metals and Metallic
Compounds, 1980), which contaminates crops. This has negative implications on rice,
which is ten times more effective at absorbing arsenic compared to other grains (Schmidt,
2015). Given the strong evidence of adverse health effects that can be attributed to iAs
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exposure, understanding the metabolism of this metalloid is a necessary part to elucidating
its role in carcinogenesis.
iAs comes in two forms: arsenite (As3+) and arsenate (As5+), of which As3+ is the
more common of the two. Once in the body, iAs can be metabolized by participation in
oxidation-reduction reactions and methylation. This happens when As5+ is reduced to As3+
and this product can undergo oxidative methylation. The methylation of As3+ plays an
important role in the metabolism of iAs as it is converted into mono-methylated (MMA)
and di-methylated (DMA), which are secreted in urine. DMAs are the predominant
metabolite secreted in the urine, accounting for 60-80% of iAs (Drobna, Styblo, & Thomas,
2009). Subsequent studies on methylated arsenals found these metabolites were strong
cytotoxins and inhibitors of enzymes, even more so than As3+ (Thomas, Styblo, & Lin,
2001). Taken together, it should be known that the metabolism of iAs produces more
reactive species that could play a role in the toxicity and carcinogenic of arsenic. An
alternative model of the methylation of arsenic has been proposed. Instead of undergoing
oxidative methylation, arsenic is bound to cellular thiols and this is the substrate for its
methylation. The formation of the arsenic-thiol complexes, which could be cellular thiols
or in glutathione (GSH), which undergo hydrolysis rather than oxidative methylation
(Hayakawa, Toru, Kobayashi, Cui, & Hirano, 2005).
The Role of Arsenic and Carcinogenesis
The mechanisms of which arsenic causes the development of cancer in humans has
not been fully elucidated. As previously illustrated, the metabolism of arsenic may induce
the production of toxic free radicals, which can cause damage to lipids, proteins, and
deoxyribonucleic acid (DNA). In addition, As3+ exposure to multiple mammalian cell lines
induced the expression of mitogen-activated protein kinase (MAPK) pathways,
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intermediate early genes (IEGs), and the activation of the transcription factor activator
protein 1 (AP-1) (Beyersmann, 2002). The expression of these pathways and genes
supports the hypothesis that cell proliferation occurs in response to arsenic, which may lead
to neoplastic growth. Furthermore, other studies found that As3+ inhibited the activation of
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) by the inhibition of
I-κB kinase, which is required for phosphorylation and subsequent degradation of the I-κB
inhibitor (Kapahi, et al., 2000). This in turn leads to a down regulation of NF-κB induced
genes and stimulation of cell proliferation.
Arsenic and its Implications in Urinary Carcinoma
There is mounting evidence showing arsenic is carcinogenic to humans,
specifically causing cancers of the bladder, lung, kidney, and skin. With millions of people
around the globe consuming drinking water contaminated with arsenic, this is a significant
cause of urinary carcinoma. The current United States drinking water standard for arsenic
is at or below a concentration of 10 parts per billion, but it is estimated that over 300,000
people drink water with arsenic levels above the set standard level (Corporation, 1987).
The most extensive epidemiological studies on the effects of iAs and urinary
carcinoma were conducted on a population of individuals that inhabited the southwest coast
of Taiwan. With deep artesian wells contaminated with arsenic, endemic rates of blackfoot
disease, pigmented, and hyperkeratotic skin lesions were detected. This prompted
researchers to study rates of cancer in the area and found the mortality risk ratios for bladder
cancer was 28.7 for men and 65.4 for women at the highest level of arsenic exposure, where
a risk ratio of greater than one is interpreted as the outcome is increased by the exposure
(Smith, et al., 1992). Despite this promising looking evidence, it has been suggested that
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the arsenic in the water was not the sole cause of cancer and averages from large groups
instead of individual exposure data was used to draw conclusions, which may render this
study showing false results.
More recent studies have considered the criticisms of the study in Taiwan and
provided evidence that ingested arsenic does indeed lead to the development of urinary
carcinoma. Two large studies took place in South America, the first being in a province of
Argentina called Cordoba. The study found the average level of arsenic in their drinking
water to be 178µg/L, which caused their mortality rates of urinary carcinoma to be double
the national average (Hopenhayn-Rich, et al., 1996). The second study which took place in
Northern Chile found mortality of urinary carcinoma was six to eight fold higher in a
population exposed to river water with arsenic levels of approximately 600µg/L (Smith,
Goycolea, Haque, & Biggs, 1998).
Contrary to the aforementioned studies, a population-based case-control study in
southeastern Michigan exposure individuals to between 10 and 100µg/L of arsenic found
no increase in urinary carcinoma risk. This study included 411 cases of cancer and found
when comparing those who were exposed to >10µg/L to those who were exposed to
<1µg/L, there was no evidence an association between arsenic exposure at low-level
concentrations and urinary cancer (Meliker, et al., 2010).
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Figure 2. Proposed mechanisms of arsenic toxicity and carcinogenesis (Adapted from Kitchin & Wallace, 2007 and Li & Chen,
2016).
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Exposure and Metabolism of Cadmium
Humans are exposed to Cd2+ via a few sources such as inhalation of industrial
pollution, contamination of top soil, which is absorbed into growing plants, and cigarette
smoking. The average human intakes between 1-3µg/day of cadmium and this amount is
doubled in smokers who consume a pack a day (Registry, 2012). The half-life of Cd2+ in
humans is estimated to be more than 20 years (Satarug, et al., 2005), which allo ws it to
be efficiently trapped in the body and cause toxicity.
Once Cd2+ is in the body, it is transported via receptors in different types of cells
where it undergoes metabolism by binding to members of the metallothionein (MT) family.
MTs are proteins that are rich in cysteine and the major zinc-binding protein (Klaassen,
Liu, & Choudhuri, 1999). By binding to MTs, Cd2+ is unable to participate in other
reactions and is subject to detoxification. A second intracellular Cd2+ scavenger is
glutathione (GSH), an intracellular thiol. The Cd2+-GSH complex leads to the
detoxification of Cd2+ (Mah & Jalilehvand, 2010).
The Role of Cadmium and Carcinogenesis
Exposure to Cd2+ has many implications in the body, such as induction of IEGs and
other detoxifying genes, increased production of reactive oxygen species (ROS), and
interactions with DNA damage repair systems. Similar to arsenic, Cd2+ induced the
overexpression of IEGs, which play a role in the stimulation of cell proliferation. This
implicates Cd2+ toxicity in promoting multi-stage carcinogenesis (Cohen, 1998). Under
physiological conditions, Cd2+ does not participate in reduction-oxidation reactions, but
oxidative stress is implicated to play a role in cadmium-induced carcinogenesis. A study
found increased levels of ROS both in vitro and in vivo, which is mediated by Cd2+ exerting
an inhibitory effect on antioxidant enzymes (Lui, Qu, & Kadiiska, 2009). These reactive
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species could lead to chromosomal aberrations, gene mutations, and DNA damage (Joseph,
2009).
There is evidence that Cd2+ disrupts three types of DNA repairs systems: base
excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR).
Under normal conditions, BER corrects small lesions in the DNA by glycosylases that
identify damaged bases, recognition of apyrimidinic/apurinic sites, cleavage of these sites,
and synthesis the correct bases by DNA polymerase (Memisoglu & Samson, 2000). Cd2+
affects the initial step of BER, the recognition and removal of damaged bases by inactivated
proteins involved in these steps . (Giaginis, Gatzidou, & Theocharis, 2006). NER functions
to correct larger, damaged pieces of DNA by unwinding the DNA, generating incisions
and excising the DNA, and repair by DNA polymerase and ligase (Costa, Chiganças, da
Silva Galhardo, Carvalho, & Mench, 2003). It has been found that Cd2+ by substituting
itself for zinc and by binding to negatively charged molecules and changing the
confirmation and disturbing DNA-protein interactions that are essential for the repair
process (Giaginis, Gatzidou, & Theocharis, 2006). MMR systems repair DNA mismatches
that occur from replication and recombination by recognizing and excising the incorrect
DNA and synthesizing the correct DNA using the parental strand as a template (Hsieh,
2001). Like BER, Cd2+ affects the initial step of base repair by interfering with ATP
binding and the hydrolysis enzymes of MMR enzymes, which reduce the ability of their
binding affinity and their function to discriminate between correct and mismatched bases
(Giaginis, Gatzidou, & Theocharis, 2006).
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Cadmium and its Implications in Urinary Carcinoma
Epidemiological studies focusing on the association between Cd2+ and urinary
carcinoma have found contradicting studies which show both no evidence and significant
evidence of this association. A study that looked at the concentrations of Cd2+ in red blood
cells and plasma found no significant difference in those with urological malignancies
compared to those with benign diseases (Feustel & Wennrich, 1986). A more recently
conducted case-controlled study in Montreal, Canada found a weak association between
occupational exposure to Cd2+ and an increased risk of urinary carcinoma (Siemiatycki,
Dewar, Nadon, & Gérin, 1994). Furthermore, two case-controlled studies in Tunisia and
Belgium found increased levels of Cd2+ blood concentrations were associated with an
increased risk of bladder cancer (Feki-Tounsi, et al., 2013) (Kellen, Zeegers, Hond, &
Buntinx, 2007). Taken together, albiet the study by Feustel & Wennrich found no evidence
of urinary carcinoma and Cd2+ exposure, others studies have demonstrated an association
between increased risk of urinary carcinoma and Cd2+ exposure.
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Figure 3. Proposed mechanisms of cadmium toxicity and carcinogenesis (Adapted from Waisberg, Joseph, Hale, & Betersmann,
2003).
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Experimental Models
UROtsa
The UROtsa model was initially cultured from ureter cells of a 12-year old female
and subsequently immortalized via the SV40 large T antigen. Although immortalized, the
cells did not display properties of neoplastic cells such as growth on soft agar and
subsequent tumor development in athymic mice (Petzoldt, Leigh, Duffy, Sexton, &
Masters, 1995). These cells form an undifferentiated monolayer in culture, but under
serum-free conditions have shown to undergo partial differentiation and resemble
structures of the intermediate layer of the bladder; specifically there were areas of
multicellular organoid structures that contained abundant intermediate filaments
resembling a differentiated intermediate layer of the bladder urothelium. (Rossi, et al.,
2001). In addition, the UROtsa cell line was transformed via exposure to 1µM sodium
arsenite (NaAsO2) or 1µM cadmium chloride (CdCl2), which led to the creation of six
As3+ and seven Cd2+ independently transformed cell lines. In contrast to the parental cell
line, both of the transformed lines produced growth of colonies on soft agar and tumors in
athymic mice (Sens, et al., 2004). Taken together, this model allows for comparison
between the cultured cell lines and their corresponding heterotransplant tumors.
Goals of the Present Study
This study was performed in two parts in order to further our understanding of
muscle-invasive urinary carcinoma and cancer stem cells isolated from the cancer cell
lines. Muscle-invasive bladder cancer has been shown to have 5-year survival rates of
only 15% of patients who have been diagnosed with stage T4 urinary carcinoma (Goebell
& Knowles, 2010). In the first part of the study, we first sought to determine if
heterotransplant tumors generated from the transformed UROtsa cell culture model are
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enriched in markers of the basal subtype of muscle-invasive urinary carcinoma.
Secondly, was to determine if the UROtsa cell lines transformed by As3+ and Cd2+ also
reflect the basal subtype of muscle-invasive urinary carcinoma and if this subtype
signature is enriched in the putative cancer stem cells isolated from the corresponding
transformed cell lines. Lastly, we wish to determine if the parental UROtsa cell line
contains a population of putative cancer stem cells, which have a gene signature of the
basal subtype of muscle-invasive bladder cancer. To address the above questions, we
determined the expression level of 9 basal and 16 luminal markers in the heterotransplant
tumors, cell lines, and spheroids, and performed western blotting of the cell lines and
immunohistochemical staining of tumors. By understanding which subtype of muscleinvasive urinary carcinoma our model system fits, we can further characterize our
UROtsa model and can study a toxicity-based carcinogenic model of muscle-invasive
bladder cancer.
The second part of this study was to determine the stability of the putative cancer
stem cell gene signature of the parental UROtsa and As3+ and Cd2+ transformed isolated
cancer stem cells when cultured under conditions identical to the parent culture and
serum-free culture conditions, which are used to isolate the cancer stem cells. Our
laboratory has previously cultured the parental UROtsa cells under serum-free culture
conditions and found the cells, once confluent, developed multicellular organoid
structures containing intermediate filaments and cells located apically in the structures
appeared to be more differentiated (Rossi, et al., 2001). To do this, triplicate samples of
the putative cancer initiating cells were grown in regular culture flasks in serumcontaining media or in serum-free media. Total RNA samples were isolated when the
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spheroids reach confluency (P1), and passages 4 and 8 (P4 and P8). The ability to
investigate the differences found in the gene expression between the original cell line and
its spheroid and the stability of the gene signature will allow us to better understand the
interactions of these two distinct cell populations in culture and how putative cancer stem
cells react with their culture environment in chronic response studies.
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CHAPTER II
METHODS
Cell Culture
UROtsa cells were initially cultured and developed in order to provide an in vitro
model of normal urothelium (Petzoldt, Leigh, Duffy, Sexton, & Masters, 1995) and
further characterized in this laboratory (Rossi, et al., 2001). The cells were cultured in
serum-containing media, which was composed of Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich, St. Louis, MO; D5523) supplemented with 5% vol/vol fetal
bovine serum (FBS) (Gibco/ThermoFisher Scientific, Grand Island, NY; 16000-044) and
serum-free media, which was composed of of a 1:1 mixture of DMEM and Ham’s F-12
(Sigma-Aldrich, St. Louis, MO; N6760) supplemented with insulin (5g/mL), transferrin
(5g/mL), hydrocortisone (36ng/mL), epidermal growth factor (10ng/mL), selenium
(5ng/mL), and triiodothyronine (4pg/mL). Both types of media cultures were incubated at
37°C in 5% CO2:95% air atmosphere. Upon reaching confluency, cells were subcultured
at a 1:4 ratio using trypsin-EDTA (0.05%, 0.02%) and fed fresh growth medium every
three days.
In the interest of gaining valuable knowledge of the toxic effect of As3+ and Cd2+
on urothelial cells, a model of metal-induced urothelial carcinoma was created using the
UROtsa bladder cell line. To do this, UROtsa cells were transformed by culturing the
cells with media which contained either 1µM NaAsO2 (Sigma-Aldrich, St. Louis, MO;

39

S7400) or 1µM CdCl2 (Sigma-Aldrich, St. Louis, MO; C1016). The cells were continued
to be exposed to these metals and were tested for their ability to form colonies on soft
agar every 5 passages (Sens, et al., 2004).
For the formation of the spheroids, cells from the parental UROtsa, six As3+ and
seven Cd2+-transformed cell lines were seeded in T-25cm2 Ultra-low attachment flasks
(Corning Inc., Corning NY; CLS3815) at a density of 1 x 105 cells. The serum-free
growth medium for these cells is mentioned above. The cells were allowed to form
spheres for eight days before harvesting by centrifugation for RNA isolation.
Animals
The mouse heterotransplants were produced as previously described (Sens, et al.,
2004). Briefly, the As3+ and Cd2+-transformed cell lines were injected at a dose of 1 x 106
cells in the dorsal thoracic midline of athymic nude (NCr-nu/nu) mice. Mice were
sacrificed ten weeks post-implantation or when clinical conditions dictated by CO2
inhalation and euthanasia and conformed to American Veterinary Medical Association
Guideline on Euthanasia. This study was approved under protocol IACUC #1117-2C by
the University of North Dakota Care Committee and adhered to all recommendations in
the Guide for the Care and Use of Laboratory Animals of the NIH.
RNA Isolation and Real-Time RT-PCR
After cells were harvested by cell scraping and pelleted via centrifugation, total
RNA was isolated using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH;
TR 118) according to manufacturer’s instructions. Total RNA of 0.1µg was purified from
the cell lines, urospheres, and tumor heterotransplants and subjected to cDNA synthesis
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA;
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1708891BUN) in a total volume of 20µL. Real-time RT-PCR was performed using the
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA;
1725274) with 2µL of cDNA and 0.2µM of primers (Bio-Rad Laboratories, Hercules,
CA and Qiagen, Valencia, CA) in a total volume of 20µL in a CFX96 Touch Real-Time
PCR Detection System (Bio-Rad Laboratories, Hercules, CA; 1855195). Cycling
parameters are as follows: denaturation at 95°C for 15 seconds, annealing at 60°C for 30
seconds, and an extension at 72°C for 30 seconds and amplification was monitored via
SYBR green fluorescence.
Immunohistochemistry
Tumor tissue from mouse tumor transplants was fixed in 10% neutral-buffered
formalin for 16-18 h. The fixed tissue samples were transferred to 70% ethanol and
dehydrated in 100% ethanol. The dehydrated tissue samples were cleared in xylene,
infiltrated, and embedded in paraffin. Serial sections were cut at 3-5µm for use in
immunohistochemical protocols. Prior to immunostaining, sections were immersed in
preheated Target Retrieval Solution (Dako, Carpinteria, CA) and heated in a steamer for
20 min. The sections were allowed to cool to room temperature and immersed into TBST for 5 min. The primary antibodies were localized using Dako peroxidase conjugated
EnVision plus for rabbit primary antibodies or a Dako peroxidase conjugated EnVision
plus dual link antibody for mouse primary antibodies at room temperature for 30 min.
Liquid diaminobenzidine (Dako) was used for visualization. Counter staining was
performed for 8 min. at room temperature using Ready-to-use Hematoxylin (Dako).
Slides were rinsed in distilled water, dehydrated in graded ethanol, cleared in xylene, and
cover-slipped. Two pathologists judged the presence and degree of immune-reactivity in
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the specimens. The scale used was 0 to +3 with 0 indicating no staining, +1 staining of
mild intensity, +2 staining of moderate intensity, and +3 staining of strong intensity.
Table 1. Immunohistochemical Analysis Antibodies
Antigen
Keratin 1
Keratin 5
Keratin 6
Keratin 7
Keratin 14
Keratin 16
Keratin 17
Keratin 19
Keratin 20
CD44
P-cadherin
TP63
CD24

Source
Invitrogen
Invitrogen
Santa Cruz
Dako (Agilent)
Invitrogen
Abcam
Dako (Agilent)
Abcam
Invitrogen
R&D Systems
Santa Cruz
Abnova
Invitrogen

Cat. No.
PA5-26699
PA5-29670
sc-514520
M7018
PA5-16722
ab8741
M7046
ab15463
PA5-22125
MAB7045
sc-7893
MAB10290
MA5-11833

Dilution/Concentration
1:100
1:400
1:500
1:50
1:400
1:40
1:20
1:100
1:100
10g/ml
1:200
1:100
1:10

Statistical Analysis
Statistical analysis consisted of Fisher’s LSD testing performed by Graphpad
PRISM 7.02. All experiments were done in triplicates and the data is plotted as the mean
± SEM or ± SD of triplicate determination.
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CHAPTER III
RESULTS
Basal and luminal marker gene expression in As3+ and Cd2+-transformed UROtsa
cell derived tumor transplants
The gene signature patterns that identify normal and malignant breast cancer
tissue has led researchers to study if these unique patterns exist in other tissue types. Choi
and coworkers identified 25 marker genes (Table 2) that define the basal and luminal
subtype of muscle-invasive bladder cancer (MIBC) (Choi, et al., 2014). Using these
genes, the expression of tumor transplants generated from the As3+ and Cd2+-transformed
UROtsa cells was determined to see if they associated with the basal or luminal subtypes
of MIBC. To do this, total RNA was isolated from the tumors of the six As3+ and seven
Cd2+-transformed cell lines and subjected to real-time RT-PCR analysis of the 25 marker
genes. In addition, the tumors were analyzed for and then normalized to five
housekeeping genes, ACTB (β-actin), B2M (β-2-microglobulin), HPRT1 (hypoxanthine
phosphoribosyltransferase 1), RPLP0 (60S acidic ribosomal protein P0), and UBC
(ubiquitin C). This was done so that direct comparison of the mRNA from the UROtsa
tumors and the 73 primary MIBCs selected by Choi could be compared (Choi, et al.,
2014)
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Table 2. Real-Time RT-PCR Analysis Primers
Gene

Molecular Subtype

Catalog No./Unique
Assay ID No.

Company

CD24
CYP2J2
ERBB2
ERBB3
FABP4
FGFR3
FOXA1
GATA3
GPX2
KRT7
KRT8
KRT18
KRT19
KRT20
PPARG
XBP1
CDH3
CD44
KRT1
KRT5
KRT6A
KRT6B
KRT6C
KRT14
KRT16
KRT17
TP63

Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
Basal
Basal
Basal
Basal
Basal
Basal
Basal
Basal
Basal
-

QT00216811
qHsaCID0016825
qHsaCID0012766
qHsaCID0018397
qHsaCID0036778
qHsaCED0042267
qHsaCED0002547
qHsaCID0017793
qHsaCID0014084
qHsaCED0038533
qHsaCED0038745
qHsaCED0035037
qHsaCED0046788
qHsaCID0007981
qHsaCED0044425
qHsaCID0010491
qHsaCID0015341
qHsaCID0013679
qHsaCID0011275
qHsaCED0005398
qHsaCED0036985
qHsaCED0003069
qHsaCED0046712
qHsaCED0047868
qHsaCED0047866
qHsaCID0023841
qHsaCIP0039056

Qiagen
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad

Following normalization, a Principal Component Analysis (PCA) was performed
on the integrated data. The first principal component explained 52.63% of the total
variation and the second principal component explained a further 17.43%, which totals to
70.06% of the total variation explained in these two principal components. As visualized
in the PCA plot (Figure 4A), the transplanted tumors generated from the As3+ and Cd2+transformed UROtsa cell lines had similar expression patterns, except for one sample
(As#5), in the first principal component, PC1. In addition, total RNA isolated from the
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parental UROtsa cells was subjected to PCA and it was found to be distinct from the
MIBC and As3+ and Cd2+-transformed tumor samples.
Unsupervised hierarchical clustering was employed to determine the tumor
subtypes of the As3+ and Cd2+ transformed tumors. Analysis of the data found that the
samples clustered into three distinct groups located at the top, middle, and bottom of the
dendrogram (Figure 4B). The group at the top showed high expression of the luminal
marker genes and low expression of the basal marker genes. Conversely, the group at the
bottom showed low expression of the luminal marker genes and high expression of the
basal marker genes. The group located in the middle showed neither high nor low
expression of the basal and luminal marker genes. All of the tumor transplants generated
by the As3+ and Cd2+ transformed cell lines clustered with the basal subtype of MIBC
located at the bottom of the dendrogram. The cluster made by the UROtsa samples can be
further divided into two subtypes: one that consists of six tumors from the Cd2+
transformed cells (Cd #2, Cd #4, Cd #5, Cd #6, and Cd #7) and three isolates of the As3+
(As #2, As #3, and As #5) and the second which consist of one Cd2+ isolate (Cd #1), three
As3+ isolates (As #1, As #4, and As #6). The parental UROtsa cell line sample has a
distinct expression pattern not associated with any of the three subtypes.
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Figure 4. Gene expression pattern analysis in the As3+ and Cd2+ tumor transplants.
(A). Principal component analysis (PCA) plot of the As3+ and Cd2+ tumor transplants,
MIBCs, and parental UROtsa cell line. The principal components, PC1 and PC2, were
calculated form the 25 MIBC marker genes. (B). Heat map and dendrogram of the 25
MIBC marker genes. Each column represents one of the 25 marker genes and each row
represents a tumor sample. The dendrogram was generated using hierarchical clustering
based on Pearson’s dissimilarity and Ward’s linkage.
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The expression of 25 MIBC marker genes was determined for the tumor
heterotransplants generated from the six independent isolates of the As3+ and seven
independent isolates of the Cd2+-transformed UROtsa cells (Figure 5A and 5B). Analysis
of the gene expression profiles demonstrated a clear trend for higher expression of genes
associated with the basal subtype of MIBC. A few exceptions were noted; the first was
that all the tumors displayed low expression P-cadherin (CDH3), a marker of basal
MIBC. The second was the elevated expression of KRT19 compared to the other luminal
marker genes.
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Figure 5. Gene expression analysis of basal and luminal marker genes in the
heterotransplant tumors produced by the As3+ and Cd2+-transformed UROtsa cells.
Real-time RT-PCR analysis of basal and luminal marker genes in the As3+ (A) and Cd2+
(B) heterotransplants. The analysis was done in triplicates and plotted as ± SD on a log
base 2 scale per transcript of β-actin times 1,000.
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Immunohistochemical expression and localization in As3+ and Cd2+-transformed
UROtsa cell derived tumor transplants
Immunohistochemical analysis was executed on tumors generated from the As3+
and Cd2+-transformed cells lines in order to determine the localization and expression
level of the basal and luminal marker genes. Except for CHD3, there was positive
staining for all of the basal markers in the tumors. A representative staining of each of the
basal markers is shown for the tumor generated from the As3+ (As #3) (Figure 6) and
Cd2+ (Cd #3)-transformed cell line (Figure 7). An independent assessment by two
pathologists found the percent of individual tumors with positive staining for each basal
marker in conjunction with the level of expression judged on a scale from 0 to +3 (Table
3) and the percent of tumor cells stained for each of the basal markers. The level of
expression for each of the basal markers was found to be strong for the tumors, with
expression intensities between +2 and +3. KRT5 was found to the basal marker with the
highest percentage of stained tumor cells, with percentages between 70 and 90%. The
lowest number of stained tumor cells was found when staining for KRT16, with
percentages between 5 and 50%. The other basal markers were found to be intermediate
between these two markers and generally followed the pattern of KRT5 > KRT1 >
KRT14 ≥ CD44 > KRT6 > KRT16. No correlation was found between the mRNA levels
of the individual tumor isolates and staining intensities for the basal marker genes.
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Table 3. Immunostaining of basal protein markers in As3+ and Cd2+ tumor transplants.
Group
As #1
As #2
As #3
As #4
As #5
As #6
Cd #1
Cd #2
Cd #3
Cd #4
Cd #5
Cd #6
Cd #7

KRT1
INT
%
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+

60
50
50
40
40
70
50
50
70
80
80
70
80

KRT5
INT
%
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+

90
80
90
90
80
90
90
70
90
90
90
90
90

KRT6
INT
%
3+
3+
3+
3+
2+
3+
3+
2+
3+
3+
3+
2+
3+

20
60
60
60
60
40
60
20
40
40
40
40
20

INT: Intensity of staining
% : % of cells staining for a marker
3+ : Strong staining
2+ : Moderate staining
2-3+ : Moderate to strong staining
1+ : Weak staining
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KRT14
INT
%
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+

90
80
80
90
30
90
90
60
30
50
60
60
50

KRT16
INT
%
3+
3+
3+
3+
3+
3+
3+
1+
2+
2+
2+
2+
2+

10
40
20
50
20
40
40
<5
10
20
20
10
10

CD44
INT
%
3+
3+
3+
3+
3+
3+
3+
3+
2-3+
2-3+
2-3+
2-3+
2-3+

70
60
30
70
30
50
40
70
40
50
30
50
50

Figure 6. Immunohistochemical staining for basal gene markers in heterotransplant
tumors generated from the As3+ transformed cell line (As #3). (A) CDH3. There is no
staining in the well-differentiated or less differentiated areas of the tumor transplants. (B).
CD44. There is no to weak staining in the center of the tumor nests, whereas the less
differentiated peripheral cell membranes stain strongly for CD44. (C). KRT1. There is
strong staining in the well-differentiated areas of the tumor, whereas the less
differentiated cells show weak staining. (D). KRT5. There is strong staining in both the
well-and less differentiated of the tumor. (E). KRT6. There is strong staining in the welldifferentiated areas of the tumor, while the less differentiated areas show no to weak
staining. (F). KRT14. The well-differentiated cells in the center of the tumor nests show
no to weak staining and the less differentiated peripheral cells are strongly positive for
KRT14. (G). KRT16. There is strong staining for KRT16 in the well-differentiated cells,
whereas the less differentiated cells show no staining. * Indicates well-differentiated
areas of the tumor. # indicates less differentiated areas of the tumor. The blue/purple
color indicates the nuclei which are counterstained with hematoxylin and the brown color
is indicative of the presence of the protein. Images are at a magnification of 200X.
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Figure 7. Immunohistochemical staining for basal gene markers in heterotransplnat
tumors generated from the Cd2+ transformed cell line (Cd #3). (A) CDH3. There is no
staining in the well-differentiated or less differentiated areas of the tumor transplants. (B).
CD44. There is no to weak staining in the center of the tumor nests, whereas the less
differentiated peripheral cells stain strongly for CD44. (C). KRT1. There is strong
staining in the well-differentiated, areas of the tumor, whereas the less differentiated cells
show weak staining. (D). KRT5. There is strong staining in both the well-and less
differentiated of the tumor. (E). KRT6. There is strong staining in the well-differentiated
areas of the tumor, while the less differentiated areas show no to weak staining. (F).
KRT14. The well-differentiated cells in the center of the tumor nests show no to weak
staining and the less differentiated peripheral cells are strongly positive for KRT14. (G).
KRT16. There is strong staining for KRT16 in the well-differentiated cells, whereas the
less differentiated cells show no staining. * Indicates well-differentiated areas of the
tumor. # indicates less differentiated areas of the tumor. The blue/purple color indicates
the nuclei which are counterstained with hematoxylin and the brown color is indicative of
the presence of the protein. Images are at a magnification of 200X.
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The immunohistochemical analysis of the As3+ and Cd2+-transformed UROtsa cell
generated tumors identified distinct nests of cells are clusters of well-differentiated
carcinoma cells, which are surrounded by stroma. The nests consisted of centers of welldifferentiated cells with intracellular bridges and keratinization and less differentiated
basal-like cells at the periphery. The staining intensity of the basal markers was distinct
between these two areas for the tumors (Figures 6 and 7 and Table 3). It can be seen that
the basal marker CD44 showed moderate to strong staining in the less differentiated,
peripheral cells, whereas the well-differentiated cells at the center showed weak staining.
In contrast, KRT1, KRT6, and KRT16 showed strong staining in the well-differentiated
cells compared to the weakly stained less differentiated periphery cells.
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Table 4. Localization of basal protein markers in different histological areas of the As3+ and Cd2+ tumor transplants.
Group
As #1
As #2
As #3
As #4
As #5
As #6
Cd #1
Cd #2
Cd #3
Cd #4
Cd #5
Cd #6
Cd #7

Well-differentiated cells in the center of tumor nests
KRT1
KRT5
KRT6 KRT14 KRT16
CD44
3+
3+
3+
3+
3+
0-1+
3+
3+
3+
3+
3+
0-1+
3+
3+
3+
0-1+
3+
0-1+
3+
3+
3+
3+
3+
0-1+
3+
3+
2+
0-1+
3+
0-1+
3+
3+
3+
3+
3+
0-1+
3+
3+
3+
3+
3+
0-1+
3+
3+
2+
0-1+
1+
0-1+
3+
3+
3+
0-1+
2+
0-1+
3+
3+
3+
0-1+
2+
0-1+
3+
3+
3+
0-1+
2+
0-1+
3+
3+
2+
0-1+
2+
0-1+
3+
3+
3+
0-1+
2+
0-1+

3+ : Strong staining
2+ : Moderate staining
2-3+ : Moderate to strong staining
1+ : Weak staining

54

KRT1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1

Peripheral less differentiated cells
KRT5
KRT6 KRT14 KRT16
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
3+
0-1+
3+
-

CD44
3+
3+
3+
3+
3+
3+
3+
3+
2-3+
2-3+
2-3+
2-3+
2-3+

Three of the luminal gene markers showed staining in the tumor transplants
(Figure 8 and Table 5). Two of the As3+ (As #1 and As #4) and one Cd2+ (Cd #1)
transformed cell line generated tumor showed no staining for KRT7, while the rest of the
tumors showed a variable percentage of staining between 5 and 40%. When present, the
intensity of the staining was judged to be between +2 and +3. All thirteen of the tumor
samples showed staining for KRT19 with percentage intensity between 20 and 80% with
strong staining localized to the periphery which contains the less differentiated areas of
the tumor nests. The staining was localized to the less differentiated peripheral cells.
CD24 staining was detected in 1 to 40% cells of the tumor with five of the tumors have
no greater than 5% of the cells showing positive staining. The staining intensity for CD24
was between +2 and +3 for all the tumor samples and was present in the welldifferentiated areas of the tumor only.
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Figure 8. Immunohistochemical staining for luminal marker genes in the
heterotransplant tumors generated from the As3+ and Cd2+-transformed cell lines.
(A-C) Staining of the As #3 cell line generated tumor for KRT7 (A), KRT19 (B), and
CD24 (C). (A) There is strong staining in the well-differentiated cells in the center of the
tumor nests (*), while the less differentiated peripheral cells (#) are negative for KRT7.
(B) The tumor nests containing the well-differentiated cells (*) are weakly positive for
KRT19, whereas there is strong staining for the less differentiated cells (#). (C) There is
moderate to strong staining in for CD24 in the well-differentiated cells (*), as opposed to
the less differentiated peripheral cells which are absent for CD24. (D-F) Staining of the
Cd #3 cell line generated tumor for KRT7 (D), KRT19 (E), and CD24 (F). (D) There is
strong staining in the well-differentiated cells in the center of the tumor nests (*) for
KRT7, while the less differentiated peripheral cells (#) are negative. (E) The tumor nests
containing the well-differentiated cells (*) are negative or weakly positive for KRT19,
whereas there is strong staining for the less differentiated cells (#). (F) There is moderate
to strong staining in for CD24 in the well-differentiated cells (*), whereas the less
differentiated peripheral cells which are absent for CD24. The blue/purple color indicates
the nuclei which are counterstained with hematoxylin and the brown color is indicative of
the presence of the protein. Images are at a magnification of 200X.
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Table 5. Expression and localization of luminal protein markers in different histological areas of the As3+ and Cd2+
tumor transplants.
KRT7

KRT19

CD24

Group
As #1
As #2
As #3
As #4
As #5
As #6
Cd #1
Cd #2
Cd #3
Cd #4
Cd #5
Cd #6
Cd #7

INT
2+
2+
3+
2+
3+
3+
3+
2-3+
2-3+
3+

%
0
10
5
0
40
10
0
40
40
40
30
30
40

INT
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+

%
40
20
30
80
40
40
40
40
40
30
40
40
30

INT
2-3+
2-3+
2-3+
2-3+
2-3+
3+
2-3+
2-3+
2-3+
2-3+
2-3+
2-3+
2-3+

%
40
30
40
5
30
30
2
1
5
10
20
5
10

Well differentiated cells in the
center of tumor nests
KRT7
KRT19
CD24
INT
INT
INT
1+
2-3+
2+
1+
2-3+
2+
1+
2-3+
1+
2-3+
3+
1+
2-3+
2+
0-1+
3+
0-1+
2-3+
3+
1+
2-3+
3+
0-1+
2-3+
3+
0-1+
2-3+
2-3+
0-1+
2-3+
2-3+
2-3+
3+
0-1+
2-3+

INT: Intensity of staining
% : % of cells staining for a marker
3+ : Strong staining
2+ : Moderate staining
2-3+ : Moderate to strong staining
1+ : Weak staining
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Peripheral less differentiated cells
KRT7
INT
3+
3+
3+
3+
2-3+
2-3+
2-3+

KRT19
INT
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+
3+

CD24
INT
-

Basal and luminal marker gene expression in the As3+ and Cd2+-transformed
UROtsa cell lines and spheroids
The mRNA expression of basal and luminal markers was determined in the As3+
and Cd2+-transformed cell lines and spheroids isolated from these cell lines. The results
of this analysis for 9 basal markers showed that six markers were differentially expressed
in the spheroids isolated from the As3+ transformed cell lines (Figure 9A). The expression
level of KRT1 was below the level of detection in the As3+ transformed cell lines, but
showed a significant increase in the spheroids. The expression levels of KRT6B, KRT6C,
KRT14, and KRT16 were also significantly increased in the spheroids, whereas CDH3
expression was lower in the spheroids when compared to the As3+-transformed cell lines.
An identical analysis of the luminal marker genes in the As3+-transformed cell lines and
spheroids showed an increase in the expression levels of FABP4, FGFR3, and KRT20,
whereas there was a decrease in the transcription factors FOXA1 and GATA3 (Figure
9B).
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Figure 9. Gene expression analysis of basal and luminal marker genes in the As3+
transformed cell lines and their corresponding spheroids. Real-time RT-PCR analysis
of basal (A) and luminal (B) marker genes in the As3+ transformed cell lines and
spheroids. The analysis was done in triplicates and plotted as ± SD on a log base 2 scale
per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from
cell line. ** indicates significantly different at p ≤ 0.01 from cell line. *** indicates
significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at
p ≤ 0.05 from cell line p ≤ 0.0001.
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The mRNA expression of basal and luminal markers was determined in the Cd2+transformed cell lines and spheroids isolated from these cell lines. Similar results were
obtained for the basal markers in the Cd2+-transformed cell lines and spheroids with there
being an increase in expression of KRT1, KRT6B, KRT6C, KRT14, and KRT16 and a
decrease in the expression of CDH3 (Figure 10A). Analysis of the luminal marker genes
in the Cd2+-transformed cell lines and spheroids show an increase in the expression of
FABP4 and decreases in expression of CYP2J2, FOXA1, GATA3, and KRT8 (Figure
10B). These results were similar to the ones obtained in the analysis of the expression of
the As3+-transformed spheroids compared to the transformed cell line with both showing
an increase in the expression of FAPB4 and decreases in FOXA1 and GATA3. However,
the As3+-transformed cell line isolated spheroids showed significant increases in FGFR3
and KRT20, whereas the Cd2+-transformed cell line isolated spheroids showed decreases
in CYP2J2 and KRT8.
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Figure 10. Gene expression analysis of basal and luminal marker genes in the Cd2+
transformed cell lines and their corresponding spheroids. Real-time RT-PCR analysis
of basal (A) and luminal (B) marker genes in the Cd2+ transformed cell lines and
spheroids. The analysis was done in triplicates and plotted as ± SD on a log base 2 scale
per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from
cell line. ** indicates significantly different at p ≤ 0.01 from cell line. *** indicates
significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at
p ≤ 0.05 from cell line p ≤ 0.0001.
61

Parental UROtsa cells produce nodules with areas of squamous differentiation
Although the tumors generated from the As3+ and Cd2+-transformed cell lines
produced prominent areas of focal squamous differentiation, it is unknown whether or not
the parental UROtsa cells express these same areas of squamous differentiation when
placed under in vivo conditions. Because this cell line is non-tumorigenic and does not
produce tumors when injected into athymic mice, the parental UROtsa cell line and
spheroids isolated from these cells were mixed with Corning® Matrigel® and
subcutaneously injected under the skin of immune compromised (NCr-nu/nu) mice. After
seven to ten days, the subcutaneous nodules were harvested and processed. Sections were
H & E stained and examined for nests of cells (Figure 11A and 11B). It was found that
these nests were composed of irregular shaped cells with branches or angular formations.
The nodules from the parental UROtsa cells and spheroids were also stained for KRT5, to
confirm an epithelial identity, and KRT6, a marker shown to identify areas of squamous
differentiation in UROtsa tumor cells (Choi, et al., 2014). The cells stained positive for
KRT5 (Figure 11C), whereas the staining for KRT6 (Figure 11D) was negative.
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Figure 11. Histology and immunohistochemical staining of nodules formed by
UROtsa cells injected with Matrigel® in immune compromised mice. Histology of a
nodule formed by UROtsa cells at 100X magnification (A) and 200X magnification (B).
Nests of epithelial cells of various shape and size seen in the Matrigel® (arrows). Many
of the nests are irregular in shape with branches or angular formations, while a few nests
are round or oval in shape, similar to the von Brunn’s nests in the human bladder.
Immunohistochemical staining for the basal marker genes KRT5 (C) and KRT6 (D). The
epithelial nests (arrow) stain strongly for KRT5 and are absent for KRT6. The spindle
stroma cells (arrowhead) are absent in staining for KRT5 and KRT6.
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Basal and luminal marker gene expression in the parental UROtsa cell line and
spheroids
The expression of 9 basal and 16 luminal marker genes was assessed in the
parental UROtsa cell line and spheroids, which are generated from the parental cell line.
The results of the basal marker genes showed that six genes (KRT1, KRT6A, KRT6B,
KRT6C, KRT14, KRT16) were significantly elevated in the spheroids compared to the
parental cell line (Figure 12A). There was a significant decrease in the expression levels
of CDH3, CD44, and KRT5 in the parental spheroids when compared to the UROtsa cell
line. The basal marker gene expression results are similar to those found in the As3+ and
Cd2+-transformed cell lines and spheroids, with both having increased expression levels
of KRT1, KRT6B, KRT6C, KRT14, and KRT16 and decreased expression of CDH3. For
the luminal marker genes, there was a significant increase in the expression of CD24,
FABP4, and KRT20 whereas there was a significant decrease in the expression of ten
genes (CYP2J2, ERBB3, FGFR3, FOXA1, GATA3, GPX2, KRT7, KRT8, KRT18, and
KRT19) (Figure 12B).
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Figure 12. Gene expression analysis of basal and luminal marker genes in the
parental UROtsa cell line and spheroids. Real-time RT-PCR analysis of basal markers
(A) and luminal marker genes (B) in the parental UROtsa cell line and spheroids. The
analysis was done in triplicates and plotted as ± SD on a log base 2 scale per transcript of
β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from parental UROtsa
cell line. ** indicates significantly different at p ≤ 0.01 from parental UROtsa cell line.
*** indicates significantly different at p ≤ 0.001 from parental UROtsa cell line. ****
indicates significantly different at p ≤ 0.0001 from parental UROtsa cell line.
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Expression of KRT17 and TP63 in the UROtsa Model System
In addition to the 25 MIBC marker genes identified by Choi and co-workers,
research has found cytokeratin 17 (KRT17) is a basal-cell specific cytokeratin, which
when highly expressed, identifies urothelial stem cells (He, et al., 2009). For this reason,
we wished to know the expression of KRT17 in our As3+ and Cd2+ heterotransplant
tumors and found high expression of KRT17 in the six As3+ and seven Cd2+ derived
tumors (Figure 13A). Next, we analyzed protein expression via immunohistochemistry
for KRT17 in the heterotransplant tumors and found strong staining in the welldifferentiated areas of the tumor (*) and weak staining in the less differentiated cells (#)
in the As3+-derived tumor (Figure 13B). On the contrary, the Cd2+-derived
heterotransplant tumor showed weak staining in the well-differentiated cells (*) and
strong staining in the less-differentiated cells (#) (Figure 13C). Lastly, we analyzed the
mRNA expression of KRT17 in our parental UROtsa and six As3+ and seven Cd2+transformed cell lines and spheroids derived from these lines. KRT17 expression was
found to be highly expressed in the cells lines and this expression was significantly
increased in the respective spheroids (Figure 13D).
Previously, the UROtsa parent cell line was immortalized via the SV40 large Tantigen (Petzoldt, Leigh, Duffy, Sexton, & Masters, 1995). The effect of this virus is not
known, but has shown to interact with p53 (Lilyestrom, Klein, Zhang, Joachimiak, &
Chen, 2006), which in turn could influence the function of p53. For this reason, the
mRNA expression of tumor protein 63 (TP63), a member of the p53 family (Wei, Zaika,
& Zaika, 2011), was determined in the As3+ and Cd2+ UROtsa-derived tumors and was
found to be moderately to highly expressed in all the tumors (Figure 13E).
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Immunohistochemical analysis of TP63 in the heterotransplant tumors found moderate
expression in the less differentiated areas of the tumor (#) with no staining in the welldifferentiated areas of the tumor nests (*) in both the As #2 and Cd #3 cell line-derived
tumors (Figure 13 F & G). Lastly, we analyzed mRNA expression of TP63 in our
parental UROtsa and six As3+ and seven Cd2+-transformed cells lines and derived
spheroids and found high expression in the cell lines with significantly decreased
expression in the parental UROtsa and As3+ spheroid (Figure 13H).
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Figure 13. Expression of KRT17 and TP63 in the parental UROtsa and As3+ and Cd2+-transformed UROtsa model. Real-time RT-PCR of KRT17 in the
As3+ and Cd2+ tumors (A) and staining of the As #3 (B) and Cd #2 (D) cell line generated tumor for KRT17. mRNA expression of parental UROtsa, As3+ and
Cd2+ cell lines and spheroids for KRT17 (D). Real-time RT-PCR of TP63 in the As3+ and Cd2+ tumors (E) and staining of the As #3 (G) and Cd #2 (H) cell line
generated tumor for TP63. mRNA expression of parental UROtsa, As3+ and Cd2+ cell lines and spheroids (F). The analysis was done in triplicates and plotted as
± SD on a log base 2 scale per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from cell line. ** indicates significantly different at
p ≤ 0.01 from cell line. *** indicates significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at p ≤ 0.05 from cell line p ≤ 0.0001.
* Indicates well-differentiated areas of the tumor. # indicates less differentiated areas of the tumor. The blue/purple color indicates the nuclei which are
counterstained with hematoxylin and the brown color is indicative of the presence of the protein. Images are at a magnification of 200X.
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Stability of the spheroid gene signature in the As3+ and Cd2+-transformed and
parental UROtsa cells
A second goal of this study was to determine the stability of the spheroid gene
signature. This was accomplished by performing microarray analysis on triplicates of
spheroids generated from a As3+-transformed cell line (As #4) grown in regular cell
culture flasks that promote cell attachment in serum-containing media, which is also used
for the growth of the As #4 cell line. Triplicate samples were subjected to total RNA
isolation when the spheroids reach confluency (passage 1) and at passages 4 (P4) and 8
(P8). The results showed that the gene expression signature of the spheroids returned to
that of the As #4 parent cell line when placed under similar cell culture conditions. Of the
initial 4,415 differentially expressed genes in the spheroids compared to the As #4
transformed cell line, by P1 70.9% of those genes had returned to the level of expression
of the As #4 cell line. This trend continued at P4 and P8 with 89.8% and 95.7%,
respectively, of the differentially expressed genes returned to the level of the As #4
transformed parental cell line.
The growth and isolation of the spheroids utilizes low attachment plastic culture
vessels with serum-free growth media, while the parental cell lines are grown in serumcontaining media in vessels that promote cell attachment. It was demonstrated that by
growing the spheroids in serum-containing growth media in vessels promoting
attachment, the gene signature returned to that of the As #4 parental cell line. Because of
these results, we wished to know if the spheroids from the As3+ and Cd2+-transformed cell
line and parental UROtsa cell line would retain their gene signatures if they were cultured
in serum-free media in adherent culture vessels. To do this, the spheroids were cultured in
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serum-free growth media in vessels that promoted cell attachment and isolated at P1, P4,
and P8.
Analysis of the 25 MIBC marker genes in the As #4 transformed cell line,
spheroid, and passages shows that 84% of the genes are differently expressed in the
spheroid compared to the parental As #4 transformed cell line. This trend is continued in
the spheroids placed in regular attachment flasks with serum-free media; the percent of
differently expressed genes at P1 and P4 is 72, while the percentage increases to 84% at
P8 (Figure 14).

Figure 14. Number of differentially expressed genes in the spheroid and passages
compared to the As3+-transformed cell line when cultured in serum-free conditions.
The total number of genes and the number of down- and up-regulated is plotted for the
spheroids and passages cultured in serum-free media.
The mRNA expression of the basal markers showed an initial decrease in
expression of CDH3 in the spheroid, but increased expression in the passages (Figure
15A). CD44 expression showed an increase in the spheroid, but no difference between
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the parental transformed cell line and the passages (Figure 15B). The expression of KRT1
was increased in the spheroid, returned to baseline levels in P1 and P4, but saw another
increase in P8 (Figure 15C). KRT5 expression was increased in the spheroids and all
three passages (Figure 15D), whereas KRT6A showed the opposite expression and was
found to be decreased in all of the samples compared to the As #4 transformed cell line
(Figure 15E). The expression of KRT6B was increased only in the spheroids (Figure
15F), while KRT6C expression saw increases across all samples (Figure 15G). KRT14
showed a slight induction in the spheroid, but a great induction in the passages (Figure
15H). Lastly, KRT16 expression was increased in the spheroid, returned to similar levels
in P1 and P4, but showed an induction of expression by P8 (Figure 15I).
Analyzing the mRNA expression of the luminal markers found increased levels of
CD24, CYP2J2, ERbβ2, and ERbβ3 (Figure 16A-D) in the spheroids and all three
passages. There was only an increase in FAPB4 in the spheroid (Figure 16E). FGFR3
expression was increased in all the samples (Figure 16F), whereas FOXA1 showed
opposite expression, being decreased in all the samples (Figure16G). There was no
change in the expression of the transcription factor GATA3 in the spheroid and P4,
however there was found to be a decrease in P1 and increase by P8 (Figure 16H). GPX2
expression was found to be increased in the spheroid, P1, P4, and P8 (Figure 16I).
Conversely, KRT7 expression was decreased in the spheroid and passages compared to
the As #4 transformed cell line (Figure 16J). KRT8 expression was increased in the
spheroid and all three passages (Figure 16K). There was increased expression of KRT18
in P4 and P8 (Figure 16L), whereas there was an increase in expression of KRT19 in the
spheroid and all three passages (Figure 16M). KRT20 expression was found to be
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increased in the spheroid, returned to baseline in P1 and P4, but increased again in P8
(Figure 16N). The receptor PPARγ saw increased expression in the passages (Figure
16O) and the expression of XBP1 was decreased in the spheroid, but levels returned to
baseline by P1 and was found to be increased in P4 and P8 (Figure 16P).
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Figure 15. Gene expression analysis of basal marker genes in the As3+-transformed cell line, spheroids, and passages. (A-I)
Real-time RT-PCR analysis of basal markers marker genes in the As3+-transformed cell line, spheroids, and serial passages. The
analysis was done in triplicates and plotted as ± SEM per transcript of β-actin.
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Figure 16. Gene expression analysis of luminal marker genes in the As3+-transformed cell line, spheroids, and passages. (A-P)
Real-time RT-PCR analysis of luminal marker genes in the As3+-transformed cell line, spheroids, and serial passages. . The analysis
was done in triplicates and plotted as ± SEM per transcript of β-actin.
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Analysis of the 25 MIBC marker genes in the Cd #4 transformed cell line,
spheroid, P1, P4, and P8 grown in serum-free cell culture media showed that 84% of the
genes are differentially expressed in the Cd #4 transformed cell line compared to the
spheroid. This high percentage of differentially expressed genes continues in the passages
where 92% of the genes are differentially expressed in P1, 72% in P4, and 68% in P8
(Figure 17). These results are similar to what was seen in the As #4 serum-free culture
analysis with a majority of the genes being differentially expressed throughout the
spheroid and subsequent passages.

Figure 17. Number of differentially expressed genes in the spheroid and passages
compared to the Cd2+-transformed cell line when cultured in serum-free conditions.
The total number of genes and the number of down- and up-regulated is plotted for the
spheroids and passages cultured in serum-free media
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While the overall number of differentially expressed genes is similar between the As #4
and Cd #4 data sets, the Cd #4 gene expression analysis shows a higher ratio up-regulated
to down-regulated differentially expressed genes.
The mRNA expression of the basal subtype specific marker genes showed an
initial decrease in CDH3 in the spheroid followed by increased expression in the three
passages (Figure 18A). The expression of CD44 significantly increased in the passages
(Figure 18B), whereas KRT1 expression increased in the spheroid and returned to
baseline by P4 (Figure 18C). KRT5 expression was increased in the spheroids, P1, P4,
and P8 (Figure 18D). The three keratin 6 isoforms (KRT6A, 6B, and 6C) all showed
increases in the spheroid, but gradually returned to similar expression levels of the Cd #4
transformed cell line by P8 (Figure 18E-G). KRT14 expression was increased in the
spheroid and all three passages compared to the Cd #4 transformed cell line (Figure
18H), whereas KRT18 showed an increase in expression in the spheroid, but decreased in
the passages and by P8 returned to expression levels of the Cd #4 cell line (Figure 18I).
The expression of CDH3 and KRT5 was similar in the As #4 and Cd #4 data sets,
whereas KRT1 and KRT16 expression saw increases in expression in the As #4 model,
but decreases in expression in the Cd #4 samples.
The luminal gene marker expression in the Cd #4 spheroid and passages showed
an increase of expression in CD24 in the samples (Figure 19A), whereas CYP2J2 had a
decrease in expression in the spheroid, but showed a significant induction in the passages
(Figure 19B). There was no change in expression of ERbβ2 in the spheroid, but an
increase in expression in the passages (Figure 19C). ERbβ3 expression was increased in
all samples (Figure 19D), however, FAPB4 was only induced in the spheroid (Figure
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19E). The expression of FGFR3 was increased relative to the Cd #4 cell line, with the
exception being P4 (Figure 19F). The transcription factor FOXA1 expression was
decreased in the spheroid, P4, and P8, while increased in P1 (Figure 19G). GATA3
expression was increased in the spheroids and subsequent passages (Figure 19H). The
expression of GPX2 was induced in the spheroid, P1, and P8 (Figure 19I). KRT7
expression was increased in P1 and P4, but returned to baseline levels by P8 (Figure19J).
The expression of KRT8, KRT18, and KRT19 was increased in the spheroids and
passages (Figure 19K-M). KRT20 expression was induced in the spheroid and returned to
baseline levels (Figure 19N), whereas PPARγ was increased in the passages (Figure
19O). Lastly, the expression of XBP1 initially decreased in the spheroid, but was induced
in the passages (Figure 19P). The expression of the luminal marker genes CD24, ERbβ3,
FAPB4, KRT8, KRT19, and PPARγ showed similar expression levels of the spheroids
and passages compared to the As #4 or Cd #4 transformed cell line.
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Figure 18. Gene expression analysis of basal marker genes in the Cd2+-transformed cell line, spheroids, and passages. (A-I)
Real-time RT-PCR analysis of basal markers marker genes in the Cd2+-transformed cell line, spheroids, and serial passages. The
analysis was done in triplicates and plotted as ± SEM per transcript of β-actin.
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Figure 19. Gene expression analysis of luminal marker genes in the Cd2+-transformed cell line, spheroids, and passages. (A-P)
Real-time RT-PCR analysis of luminal marker genes in the Cd2+-transformed cell line, spheroids, and serial passages. . The analysis
was done in triplicates and plotted as ± SEM per transcript of β-actin.
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The mRNA expression analysis of the 25 MIBC marker genes in the UROtsa cell
line, spheroid, and passages cultured in serum-free media showed a great percentage of
the genes being differentially expressed compared to the parental cell line at the spheroid
and each passage. Analysis found 84% of the genes were differentially expressed in the
spheroid and P1, 88% in P4 and 76% in P8 (Figure 20). These trends align with the As #4
and Cd #4 serum-free cultured spheroids and passages. However, unlike those data sets,
the UROtsa expression analysis showed a greater ratio of down-regulated to up-regulated
genes.

Figure 20. Number of differentially expressed genes in the spheroid and passages
compared to the UROtsa cell line when cultured in serum-free conditions. The total
number of genes and the number of down- and up-regulated is plotted for the spheroids
and passages cultured in serum-free media.
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Analysis of the basal specific marker genes of MIBC found decreased expression
levels of CDH3 in the spheroid and passages (Figure 21A). The expression of CD44 was
decreased in the spheroid and increased in P1 and P4 (Figure 21B). KRT1 expression was
greatly induced in P4 and P8 (Figure 21C) and KRT5 showed an increase in expression
across all the samples compared to the UROtsa cell line (Figure 21D). The expression of
the keratin isoforms (KRT6A, 6B, and 6C) was increased in all the spheroids and
passages, except for P1 in KRT6A (Figure 21E-G). The expression of KRT14 was
induced in the passages (Figure 21H). Lastly, KRT16 expression was increased in the
spheroid and P1, but decreased in P4 and P8 (Figure 21I). The expression of CDH3 was
opposite of what was seen in the As #4 and Cd #4 data sets, however the expression of
KRT5 and KRT14 was alike in all three.
Analysis of the mRNA expression of the luminal MIBC marker genes found
expression of CD24, CYP2J2, and ERbβ2 to be decreased in the spheroids and passages
(Figure 22A-C). The expression of ERbβ3 was increased in the spheroid and P4, but
decreased in P1 (Figure 22D). FABP4 expression was induced in the spheroid and
decreased in P1 and P4 (Figure 22E). The expression FGFR3 was decreased in the
spheroids and increased in P1 (Figure 22F). The expression of FOXA1 and GATA3 was
decreased in the spheroids and passages (Figure 22G-H), whereas GPX2 expression was
increased in all the samples (Figure 22I). KRT7, KRT8, and KRT18 expression was
decreased in the spheroids and passages (Figure 22J-L). The expression of KRT19 was
decreased in P4 and P8 (Figure 22M), whereas expression of KRT20 was induced in the
spheroid and P1, but returned to similar levels of the UROtsa cell line by P4
(Figure 22N). Lastly, the expression of PPARγ and XBP1 were decreased in the spheroid
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and subsequent passages (Figure 22O-P). The expression of FABP4 and GPX2 in the
UROtsa serum-free culture model was similar to the results seen in the As #4 and Cd #4
data, while the expression of CD24, KRT8, and XBP1 showed opposite results.
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Figure 21. Gene expression analysis of basal marker genes in the parental UROtsa cell line, spheroids, and passages. (A-I)
Real-time RT-PCR analysis of basal markers marker genes in the parental UROtsa cell line, spheroids, and serial passages. The
analysis was done in triplicates and plotted as ± SEM per transcript of β-actin.
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Figure 22. Gene expression analysis of luminal marker genes in the parental UROtsa cell line, spheroids, and passages. (A-P)
Real-time RT-PCR analysis of luminal marker genes in the parental UROtsa cell line, spheroids, and serial passages. . The analysis
was done in triplicates and plotted as ± SEM per transcript of β-actin
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CHAPTER IV
DISCUSSION
Our laboratory has determined that the tumor transplant generated from the As3+
and Cd2+-transformed UROtsa cells display a basal gene expression pattern identified by
a recent study (Choi, et al., 2014) through two different approaches. First the expression
of mRNA for the 9 basal and 16 luminal marker genes from the tumors derived from the
six isolates of the As3+ and seven isolates of the Cd2+-transformed UROtsa cells was
compared to the 73 primary MIBCs selected for analysis in the study by Choi and
coworkers (Choi, et al., 2014). The results showed that unsupervised hierarchical
clustering of the samples found that the As3+ and Cd2+ tumors demonstrated a strong
identify with the basal subtype of MIBCs. These results were supported by comparing the
mRNA expression levels of the basal and luminal marker genes in the tumors derived
from the six isolates of As3+ and seven isolates of Cd2+-transformed cells and finding an
elevated expression of the basal compared to the luminal marker genes.
Despite the supporting results of the unsupervised hierarchical clustering and
comparison of mRNA expression levels of the marker genes, concerns regarding the high
expression of the keratins in the basal and luminal subtypes and the multiple transcription
factors associated with the luminal subtype. Because of their association with the
cytoskeleton, the keratins may have high levels of expression and transcription factors are
known to exert their influence at low expression levels. However, two of the keratins
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associated with the luminal subtype (KRT7 and KRT20), showed only modest and no
expression, respectively.
The final piece of evidence that the As3+ and Cd2+-transformed derived tumors
show characteristics of the MIBC basal subtype is the immunohistochemical expression
of the basal and luminal markers. Besides CDH3, all of the tumors showed a strong
staining for the other basal markers. Opposed to the high expression of the basal markers,
only three luminal markers showed staining in the tumor transplants (CD24, KRT7, and
KRT19). Therefore, the tumors generated from the As3+ and Cd2+-transformed parental
UROtsa cells display expression patterns that aligns with the basal subtype of MIBCs.
The characterization of the UROtsa-derived tumors as the basal subtype of MIBC
could be influenced by multiple factors. First, because of the generation of the tumors in
athymic mice, there is limited influence of immune cells on the tumors, which interrupts
the interaction of the stroma and tumor. Next, the UROtsa parent cell line was
immortalized via the SV40 large T-antigen (Petzoldt, Leigh, Duffy, Sexton, & Masters,
1995). The effect of this virus is not known, but has shown to interact with p53
(Lilyestrom, Klein, Zhang, Joachimiak, & Chen, 2006), which in turn could influence the
function of p53. For this reason, the expression of p63, a member of the p53 family (Wei,
Zaika, & Zaika, 2011), was determined in the UROtsa-derived tumors and was found to
be expressed in all the tumors.
The expression of mRNA for the basal and luminal marker genes was also
analyzed in the As3+ and Cd2+ transformed cell lines and spheroids generated from each
of the six As3+ and seven Cd2+ cell lines. These cells lines had expression patterns that
identified the most with the basal gene signature and this identity was increased in the
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spheroids isolated from the cell lines. The expression of KRT1, KRT6B, KRT6C,
KRT14, and KRT16 was increased in the spheroids compared to the As3+ and Cd2+transformed cell lines. These basal gene markers were also upregulated in the tumors
generated from the transformed cells.
The next part of this study looked at the mRNA expression of the basal and
luminal marker genes in the parental UROtsa cell line and the spheroids isolated from
these cells. The expression levels were compared to the transformed cell lines, tumors
from these cell lines, and the MIBCs. The results showed that the spheroids from the
parental UROtsa cells showed increased expression of all the basal keratins (KRT1,
KRT5, KRT6A, KRT6B, KRT6C, KRT14, and KRT16), whereas there was decreased
expression of CDH3 and CD44. The increased of expression of five of these six keratins
was seen in the spheroids isolated from the transformed cells and tumors derived from
these cell lines along with the decreased expression of CDH3. With the overlapping
increase of five out of the six basal keratins in the parental UROtsa and As3+ and Cd2+
transformed cell line derived spheroids, this suggests that these basal keratins may be
markers of urinary carcinoma with characteristics of squamous differentiation. The
results also suggests that the spheroids isolated from the parental UROtsa cells undergo
transformation with As3+ and Cd2+ and gain the ability to form tumors in aythmic mice.
The study then shifted focus and examined if the gene signature seen in the
spheroids could be maintained once the spheroids were placed back in conditions used to
grow the original cell line. The growth and isolation of the spheroids utilizes low
attachment culture vessels with serum-free growth media, in contrast to the parental cell
lines, which are grown in vessels promoting attachment with serum-containing growth
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media. Microarray analysis data found that the gene signature of the spheroids isolated
from one of the As3+-transformed cell lines (As#4) reverted back to that of the original
cell line. Upon reaching confluency, over 70% of the differentially expressed genes were
no longer expressed and seven more serial passages showed that 95% of the genes were
no longer differentially expressed. These results suggests that a culture environment of
serum-containing media does not allow for differentiation of our UROtsa model system.
In addition, a limited analysis of the 25 MIBC marker genes of the same
experimental cell culture set-up, except cultured in serum-free media, found an
expression profile for the As #3, Cd #3, and parental UROtsa cells to be different when
comparing the cell line to the spheroids and serial passages. The As #3 spheroid and
serial passages saw increases in the basal markers KRT5 and KRT14, which are markers
of the basal cell compartment of the bladder (McConkey, Choi, Ochoa, & Dinney, 2016).
The luminal markers Erb-β2 and Erb-β3 showed increases in the spheroids and serial
passages compared to the cell line, which suggests an increase in proliferation due to the
heterodimerization of these co-receptors and subsequent signaling of the PI3K pathway
(Holbro, et al., 2003). Furthermore, a knockout of FOXA1, a DNA-binding protein that
plays a role in metabolism and interactions with hormones, has resulted in the
development of keratinizing squamous metaplasia in mice (Shuman, et al., 2017). Lastly,
the results showed an increase in glutathione peroxidase 2 (GPX2), which suggests an
increase in proliferation and ROS (Naiki, et al., 2017). Taken altogether, the As #3
unique gene signature shows increased levels of growth and proliferation due to increased
expression of basal cells and reactive oxygen species furthering the development of
squamous differentiation and urinary carcinoma.
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The Cd #3 cell line showed decreases of expression in KRT5 and KRT14, similar
to those of the As #3 cell line. The luminal marker gene GATA3 was increased in the
spheroids and serial passages, which could be indicative of decreased invasion and
progression (Li, et al., 2014). Also increased in expression was the transcription factor Xbox binding protein 1 (XBP1), which has been implicated in the unfolded protein
response and shown to lead to an increase in innate immune response and a potent
cytotoxic T-lymphocyte engagement (Overley-Adamson, et al., 2014). Taken together,
there may be a unique gene signature that is less invasive and a less progressive form of
urinary carcinoma.
The parental UROtsa spheroids and serial passages showed a decrease in
expression of P-cadherin (CDH3), which has been linked to muscle-invasive disease
(Mandevilla, et al., 2008) and increases in KRT5 and KRT14. Similar to the As #3 cell
line, spheroids, and serial passages, the parental UROtsa model showed a decrease in
expression of FOXA1 and an increase in GPX2. However, the parental UROtsa model
showed decreases in the expression of GATA3, PPARγ, and XBP1. These results suggest
the parental UROtsa spheroid and serial passages have increased expression of basal cells
and invasion and disease progression.
Overall, the unique gene signatures found in the spheroids and serial passages
compared to the original cell lines indicates the role that serum has on the ability to
differentiate cells and the growth environment of cells directly influences the gene
expression of those cells and their ability to differentiate into cells with unknown
characteristics and properties.
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ABBREVIATIONS
2D

Two-dimensional

3D

Three-dimensional

AP-1

Activator protein 1

As3+

Arsenite

As5+

Arsenate

ATP

Adenosine triphosphate

BER

Base excision repair

CCND1

Cyclin D1

Cd2+

Cadmium

CD24

Cluster of differentiation 24

CD44

Cluster of differentiation 44

CdCl2

Cadmium chloride

CDH3

Cadherin 3

CYP2J2

Cytochrome P450 family 2 subfamily J member 2

DMA

Di-methylated

DMEM

Dulbecco’s modified Eagle’s medium

DNA

Deoxyribonucleic acid

EDTA

Ethylenediaminetetraacetic acid
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ERBB2

Erb-β2 receptor tyrosine kinase 2

ERBB3

Erb-β2 receptor tyrosine kinase 3

FABP4

Fatty acid binding protein 4

FGFR3

Fibroblast growth factor receptor 3

FOXA1

Forkhead box A1

GATA3

GATA binding protein 3

GC

Gemcitabine plus cisplatin

GPX2

Glutathione peroxidase 2

GSH

Glutathione

H&E

Hematoxylin and eosin

HMOX1 Heme oxygenase 1
iAs

Inorganic arsenic

IEG

Intermediate early genes

IPA

Ingenutiy pathway analysis

I-κB

Inhibitor of κB

KPNA2

Karyopherin subunit alpha 2

KRT1

Keratin 1

KRT14

Keratin 14

KRT16

Keratin 16

KRT17

Keratin 17

KRT18

Keratin 18

KRT19

Keratin 19

KRT20

Keratin 20
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KRT5

Keratin 5

KRT6A

Keratin 6A

KRT6B

Keratin 6B

KRT6C

Keratin 6C

KRT7

Keratin 7

KRT8

Keratin 8

MAPK

Mitogen-activated protein kinase

MDM2

MDM2 proto-oncogene

MIBC

Muscle-invasive bladder cancer

MMA

Mono-methylated

MMR

Mismatch repair

mRNA

Messenger RNA

MT

Metallothionein

mTOR

Mammalian target of rapamycin
Methotrexate, vinblastine, doxorubicin, and

MVAC
cyclophosphamide
NaAsO2

Sodium arsenate

NER

Nucleotide excision repair

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

PCA

Principle Component Analysis

PD-1

Programmed cell death protein

PD-L1/2 Programmed death ligand 1/2
PI3K

Phosphatidylinositol-3-kinase
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phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
PIK3CA
subunit alpha
PPARG

Peroxisome proliferator activated receptor gamma
Phosphatidylinositol (3,4,5)-trisphosphate phosphatase and

PTEN
tensin homolog
RB

Retinoblastoma

RNA

Ribonucleic acid

ROS

Reactive oxygen species

RTK

Receptor tyrosine kinase

SCC

Squamous cell carnicoma

SV40

Polyomavirus simian virus 40

TP53

Tumor protein 53

TP63

Tumor protein 63

TURBT

Transurethral resection of the bladder tumor

UPK1B

Uroplakin 1B

UPK2

Uroplakin 2

UPK3

Uroplakin 3

XBP1

X-box binding protein 1
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